A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment
Accepting New Patients
Practice Locations
A:
B:
C:
Education
Residency
Indiana University School of Medicine
Medical SchoolShanghai Medical University
FellowshipUniversity of Louisville Brown Cancer Center
Board Certifications
Medical Oncology
American Board of Internal Medicine
HematologyAmerican Board of Internal Medicine
Hospital Affiliations
- Baptist Health Medical Group
- Baptist Health La Grange
- Baptist Health Louisville
Philosophy of Care
Baptist Health Medical Group is a comprehensive, multispecialty network of physicians and advanced practice clinicians. Our providers are committed to providing compassionate, patient-centered care and strive to treat our patients the way we would want to be treated, every time, at every Baptist Health location.
Research
Cancer
thoracic cancer
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
Cancer
thoracic cancer
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
Cancer
Lung Cancer
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Cancer
Lung Cancer
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Insurance
Our providers accept many insurance plans. Check the Baptist Health insurance policy to make sure yours is one of them.